George O. Elston Named Chief Executive Officer of 2X Oncology
May 30 2017 - 12:26PM
2X Oncology, Inc. ("2X" or the "Company"), a company focused on
developing targeted therapeutics to address significant unmet needs
in women’s cancer, announces that its Board of Directors has
appointed veteran life science executive George O. Elston as its
Chief Executive Officer (CEO). Mr. Elston has also been
appointed to the 2X Board of Directors.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/0de44f57-d058-4959-955f-f37981f14892
During his over 25 years as a life sciences leader, executive
and board member, Mr. Elston has established a strong track record
of building, leading and growing businesses and advancing products
through clinical development and partnering.
"George brings broad executive experience in building and
managing biophama companies, including identifying and executing
key financing and partnering transactions,” said Peter Buhl Jensen,
M.D., DMSc, Chairman of the 2X Board.
"His recent and relevant experience in both women’s health and
oncology is a perfect tie-in to the 2X business vision and
strategy, complementing the team and strengthening our position
within the precision medicines field of drug development for
women’s cancers."
Mr. Elston was most recently the Chief Financial Officer of
Juniper Pharmaceuticals, Inc. (Nasdaq:JNP), where he played a key
role in negotiating and executing transformative technology and
financing transactions for the women’s health therapeutics
developer. He is also a member of the board of directors of
Celldex Therapeutics, Inc. (Nasdaq:CLDX) and the Deutsche Bank DBX
Trust.
"The combination of 2X Oncology’s oncology therapeutics and
novel proprietary companion diagnostics to facilitate
identification of likely responders has potential to positively and
significantly impact the approach to treating challenging women’s
cancers,” said Mr. Elston. "I am excited to join and lead 2X at
this important time in its evolution as we work to quickly move
programs into clinical development.”
2X Oncology plans to execute a Series A financing to support the
advancement of its pipeline of Phase 2 oncology products, each with
a unique Drug Response Prediction (DRP™) companion
diagnostic.
An abstract on the predictive ability of the DRP™ in treating
advanced breast cancer with epirubicin will be presented at the
2017 American Society of Clinical Oncology (ASCO) Annual Meeting in
a poster session on June 4, 2017 from 8:00-11:30am local time (Hall
A, Board #63).
Among 2X Oncology’s product candidates is a glutathione
enhanced, PEGylated liposomal doxorubicin product, 2X-111, for the
treatment of breast and brain cancer with a DRP™ companion
diagnostic. Doxorubicin is an anthracycline like epirubicin
and also used in the treatment of breast cancer.
Data from planned Phase 2 clinical trials of 2X-111 is expected
in 2018.
About 2X Oncology
2X Oncology Inc. is a is a clinical stage company developing
targeted therapeutics that leverage proprietary Drug Response
Predictor (DRP™) companion diagnostic technology to address
significant unmet needs in women’s cancer. The DRP generates
a precision mRNA-based companion diagnostic for each compound,
enabling the identification of patients that are most likely to
respond and benefit from treatment.
The 2X pipeline includes product candidates focused on breast,
ovarian, and endometrial cancers and primary and secondary brain
tumors. These programs have shown clinical efficacy and
safety and are positioned to enter focused Phase 2 studies with
data expected in 2018.
A Cambridge, MA based spin-out from Oncology Venture ApS, 2X
works in close collaboration with Oncology Venture and leverages
its Danish registry of over 1,100 cancer patients for initial
clinical studies. Learn more at 2xoncology.com.
DRP™ is a trademark of Medical Prognosis Institute A/S.
Contact
Amy Raskopf
+1 917.673.5775
amy.raskopf@2Xoncology.com
www.2xoncology.com
Twitter: @2xoncology
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Apr 2024 to May 2024
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From May 2023 to May 2024